- Location
Zytiga
"-
The Company's Robust Performance Was Driven by New and Existing Drug Sales
Apr 16, 2014The common stock of healthcare and medical device giant Johnson & Johnson (JNJ) soared to recent highs following the company's announcement of first quarter results that beat analysts' estimates. The company's robust performance was ...
Tags: Health, Medicine, medical device
-
Johnson & Johnson Has Completed The Acquisition of Aragon Pharmaceuticals
Aug 22, 2013Johnson & Johnson has completed the acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to hormonally-driven cancers. The Janssen Research & Development will manage compound ...
-
US-Based Johnson & Johnson Has Agreed to Buy Aragon Pharmaceuticals for $1bn
Jun 19, 2013US-based Johnson & Johnson has agreed to buy Aragon Pharmaceuticals, a discovery and development company focused on drugs to treat hormonally-driven cancers, for nearly $1bn. As per the acquisition agreeement, an upfront cash payment of ...
Tags: Johnson&Johnson, Medicine
-
EC Has Approved Broader Indication of Janssen-Cilag International's Oral
Jan 15, 2013The European Commission (EC) has approved broader indication of Janssen-Cilag International's oral, once-daily medication Zytiga (abiraterone acetate). Licence extension includes the use of Zytiga as a combination therapy along with ...
Tags: Zytiga, Janssen Europe, medical
-
mCRPC Has Won FDA Approval for Use in Patients Who Have Not Received Chemotherapy
Dec 11, 2012Janssen's Zytiga indicated for metastatic castration-resistant prostate cancer(mCRPC),has won FDA approval for use in patients who have not received chemotherapy. The oral,once-daily medication was previously used in combination with ...
-
Janssen Research and Development Has Received The Priority Review
Aug 30, 2012Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
-
Janssen Research Submitted a Supplemental New Drug Application to FDA for Zytiga
Jun 18, 2012Janssen Research & Development has announced that it has submitted a supplemental New Drug Application to FDA for ZYTIGA(abiraterone acetate). Janssen-Cilag International NV has also sent a type II variation to the European Medicines ...
